Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03419624
Recruitment Status : Terminated (Delay in patient enrolment)
First Posted : February 5, 2018
Last Update Posted : March 31, 2020
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

Brief Summary:
This is a 28-week, multi-center, randomized, double-blind, placebo-controlled trial to study a potential synergistic effect of Dapagliflozin plus Exenatide once-weekly in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c≥8.0% and ≤ 11.0%).

Condition or disease Intervention/treatment Phase
Obesity Diabetes Mellitus, Type 2 Drug: Dapagliflozin 10mg Drug: Exenatide 2 mg [Bydureon] Drug: Placebo Oral Tablet Drug: Placebo injection Drug: Insulin Drug: Metformin, if taken before Phase 3

Detailed Description:
In this proof-of-concept study the potential of treatment with Dapagliflozin plus Exenatide added to high-dose intensive insulin therapy compared to Placebo added to high-dose intensive insulin with active insulin up-titration for change in HbA1c from baseline to week 28 shall be explored and generate initial data on the primary outcome. We hypothesize that SGLT-2 inhibition and GLP-1 receptor agonism may be a rational combination therapy that addresses a broad range of pathophysiological defects associated with T2DM in obesity and may reduce HbA1c levels in patients with severe insulin resistance. In a third treatment arm, patients will be treated with Exenatide monotherapy added to high-dose intensive Insulin therapy to study additive effects of Dapagliflozin and Exenatide.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)
Actual Study Start Date : February 19, 2018
Actual Primary Completion Date : April 1, 2019
Actual Study Completion Date : August 5, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dapagliflozin plus Exenatide
Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
Drug: Dapagliflozin 10mg
Dapagliflozin 10 mg tablet once daily

Drug: Exenatide 2 mg [Bydureon]
Exenatide 2 mg injection once weekly

Drug: Insulin
daily Insulin injections

Drug: Metformin, if taken before
If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.

Placebo Comparator: Placebo plus Placebo
Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
Drug: Placebo Oral Tablet
Placebo oral tablet once daily

Drug: Placebo injection
Placebo injection once weekly

Drug: Insulin
daily Insulin injections

Drug: Metformin, if taken before
If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.

Active Comparator: Placebo plus Exenatide
Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
Drug: Exenatide 2 mg [Bydureon]
Exenatide 2 mg injection once weekly

Drug: Placebo Oral Tablet
Placebo oral tablet once daily

Drug: Insulin
daily Insulin injections

Drug: Metformin, if taken before
If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.




Primary Outcome Measures :
  1. Change in HbA1c from baseline (week 0) to week 28 [ Time Frame: 28 weeks ]
    To compare the absolute change from baseline in HbA1c at week 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy


Secondary Outcome Measures :
  1. Change in HbA1c from baseline (week 0) to week 14 [ Time Frame: 14 weeks ]
    To compare the absolute change in HbA1c from baseline at week 0 to week 14 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy

  2. Change in total body weight from baseline (week 0) to week 14 and 28 [ Time Frame: 28 weeks ]
    To compare the change in total body weight from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy

  3. Change in BMI from baseline (week 0) to week 14 and 28 [ Time Frame: 28 weeks ]
    To compare the change in BMI from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy

  4. Change in FPG from baseline (week 0) to week 14 and 28 [ Time Frame: 28 weeks ]
    To compare the change in fasting plasma glucose (FPG) from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy

  5. Change in TDID from baseline (week 0) to week 14 and 28 [ Time Frame: 28 weeks ]
    To compare the change in total daily insulin dose (TDID) from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy

  6. Proportion of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline [ Time Frame: 28 weeks ]
    To compare the number of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline at week 0 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For inclusion in the study patients should fulfill the following key criteria:

  1. Informed Consent can be obtained prior to any study procedures.
  2. Patient is able to read, understand and sign the Informed Consent.
  3. HbA1c ≥ 8.0% and ≤ 11.0% based on laboratory results
  4. Currently treated with a stable TDID ≥ 80 U at least 3 months prior to enrolment
  5. Patients who are receiving metformin must be on a stable total daily dose ≥ 1500 mg or the maximum tolerated dose of metformin within 3 months prior to enrolment
  6. BMI of ≥ 30 kg/m2 at enrolment
  7. Male or female and ≥18 and ≤75 years old at time of informed consent
  8. For female patients:

    • Not breastfeeding.
    • Negative pregnancy test result (human chorionic gonadotropin, beta subunit [βhCG]) at Visit 0 (Screening) and Visit 1 (randomization) -not applicable to hysterectomized and post-menopausal females.
    • If of childbearing potential (including perimenopausal women who have had a menstrual period within 1 year), must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, ie, less than 1% per year, when used consistently and correctly, such as implants, injectables, hormonal contraceptives [pills, vaginal rings, or patches], some intrauterine contraceptive devices [levonorgestrel-releasing or copper-T], tubal ligation or occlusion, or a vasectomized partner) during the entire duration of the study. As applicable, all methods must be in effect prior to receiving the first dose of study medication.
    • Must practice appropriate birth control as stated above for 10 weeks after the last dose of study medication.
  9. Patients who are receiving the following medications must be on a stable treatment regimen for a minimum of 2 months prior to Visit 0 (Screening):

    • Antihypertensive agents
    • Thyroid replacement therapy
    • Antidepressant agents

Exclusion Criteria:

  1. Diagnosis of Type 1 Diabetes
  2. History of diabetic ketoacidosis, hyperosmolar coma or corticosteroid-induced Type 2 diabetes
  3. Patients with significant thyroid disease
  4. Patients with history of acute or chronic pancreatitis
  5. Clinically significant cardiovascular disease or procedure within 3 months prior to enrolment or expected to require coronary revascularization procedure
  6. Presence of history of severe congestive heart failure (NYHA III and IV)
  7. Creatinin-Clearance of < 60 ml/min based on local laboratory results
  8. Concomitant medication with loop diuretics
  9. Patients who, as judged by the investigator, may be at risk for dehydration or volume depletion that may affect the patient's safety (including e.g. patients with a history of Diabetes insipidus)
  10. Pregnant women
  11. Administration of any other antidiabetic therapy, other than insulin (see inclusion criterion no.4 and 5) and metformin with a stable total daily dose ≥ 1500 mg or the maximum tolerated dose of metformin within 3 months prior to enrolment
  12. History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥ 700 mg/dL (≥ 7.98 mmol/L) at Visit 0 (Screening).
  13. History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis.
  14. History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.
  15. Significant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or total bilirubin (TB) >2 mg/dL (>34.2 μmol/L) (patients with TB >2 mg/dL [>34.2 μmol/L] and documented Gilbert's syndrome will be allowed to participate).
  16. Known history of hepatotoxicity with any medication
  17. Known history of severe hepatobiliary disease.
  18. Positive serological test for hepatitis B or hepatitis C.
  19. Known or suspected human immunodeficiency virus (HIV) infection.
  20. History of organ transplantation.
  21. Presence or history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) OR a family history of medullary thyroid carcinoma or MEN 2.
  22. Malignancy (with the exception of basal and squamous cell carcinoma of the skin) within 5 years of Visit 0 (Screening).
  23. Hemoglobinopathy, hemolytic anemia, or chronic anemia (haemoglobin concentration <11.5 g/dL [115 g/L] for males, <10.5 g/dL [105 g/L] for females) or any other condition known to interfere with the HbA1c methodology.
  24. Patients with abnormal test results of hematocrit (hematocrit > 50% for men; hematocrit > 47% for women)
  25. Has donated blood or had a significant blood loss within 2 months of first dose of study medication or is planning to donate blood during the study.
  26. Has donated plasma within 7 days prior to first dose of study medication.
  27. Any exposure to Exenatide (including BYETTA®, BYDUREON, or exenatide suspension).
  28. Any exposure to Dapagliflozin or any SGLT-2 inhibitor.
  29. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:

    • Any DPP-4 inhibitor within 3 months prior to Visit 0 (Screening).
    • Any GLP-1 analog within 1 year prior to Visit 0 (Screening).
    • Systemic corticosteroids within 3 months prior to Visit 0 (Screening) by oral, intravenous, intra-articular, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR) steroids known to have a high rate of systemic absorption. For examples of excluded steroids, refer to Section 7.7.
    • Prescription or over-the-counter weight loss medications within 3 months prior to Visit 0 (Screening).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03419624


Locations
Layout table for location information
Germany
Diabeteszentrum Oldenburg
Oldenburg, Lower Saxony, Germany, 23758
University Medical Center Hamburg-Eppendorf
Hamburg, Germany, 20246
Diabetologische Schwerpunktpraxis Harburg
Hamburg, Germany, 21073
Gemeinschaftspraxis für Innere Medizin und Diabetologie
Hamburg, Germany, 22607
Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Jens Aberle, MD Universitätsklinikum Hamburg-Eppendorf
Publications:
Sharma S, Jain S. Prevalence of Obesity among Type-2 Diabetics. J Hum Ecol 2009;25:31-5.
2012. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus n.d. ema.europa.eu.
EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes 2016. www.ema.europe.eu.
FDA approves Farxiga to treat type 2 diabetes. 2014 n.d. fda.gov.
FDA Approves Bydureon Pen. 2014 n.d. drugs.com.

Layout table for additonal information
Responsible Party: Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier: NCT03419624    
Other Study ID Numbers: UKE-DapEx-001
First Posted: February 5, 2018    Key Record Dates
Last Update Posted: March 31, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Universitätsklinikum Hamburg-Eppendorf:
Dapagliflozin
Exenatide
high-dose insulin therapy
SGLT-2 inhibitor
GLP-1 receptor agonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Metformin
Dapagliflozin
Exenatide
Hypoglycemic Agents
Physiological Effects of Drugs
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Obesity Agents
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists